PMID- 23265095
OWN - NLM
STAT- MEDLINE
DCOM- 20130513
LR  - 20161125
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
VI  - 29
IP  - 4
DP  - 2013 Apr
TI  - Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: 
      IMPACT-CABG pilot trial.
PG  - 441-7
LID - S0828-282X(12)01213-5 [pii]
LID - 10.1016/j.cjca.2012.08.009 [doi]
AB  - BACKGROUND: The Implantation of Autologous CD133(+) Stem Cells in Patients 
      Undergoing CABG (IMPACT-CABG) trial is investigating the feasibility, safety, and 
      efficacy of intramyocardial injections of autologous CD133(+) stem cells during 
      coronary artery bypass grafting (CABG) in patients with chronic ischemic 
      cardiomyopathy. We are reporting the results of the first 5 open-label patients. 
      METHODS: Bone marrow was harvested from iliac crests and stem cells were isolated 
      using the CliniMACS CD133(+) Reagent System (Miltenyi Biotec, GmbH, Bergisch 
      Gladbach, Germany). Patients received CABG, followed by CD133(+) cellular 
      injection in the revascularized hypokinetic myocardium. RESULTS: Five males New 
      York Heart Association (NYHA) class III patients aged 64 +/- 10 years were treated. 
      Immunomagnetic cell processing allowed an average of 100 +/- 48-fold enrichment in 
      CD133(+) cells, with 92 +/- 11% recovery after selection. Mean number of CD133(+) 
      cells injected was 8.4 +/- 1.2 million. There were no protocol-related 
      complications during the 18-month follow-up and all patients improved to NYHA 
      class I. Six-month echocardiography showed no significant improvement in left 
      ventricular ejection fraction (34 +/- 2% at baseline vs 38 +/- 12%: P = 0.50). 
      However, cardiac magnetic resonance showed that systolic wall thickening 
      increased from 15.0 +/- 10.5% to 29.0 +/- 22.1% (P = 0.01). In addition, mean 
      segmental wall thickness also improved in comparison with baseline (10.7 +/- 2.7% 
      to 12.1 +/- 4.8%; P < 0.01). CONCLUSIONS: This work represents the first Canadian 
      experience with CD133(+) stem cells for the treatment of chronic ischemic 
      cardiomyopathy. These results demonstrate the initial safety and feasibility of 
      the IMPACT-CABG pilot trial. Subsequent patients are now being randomized to 
      receive either CD133(+) stem cell or placebo.
CI  - Copyright (c) 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All 
      rights reserved.
FAU - Forcillo, Jessica
AU  - Forcillo J
AD  - Division of Cardiac Surgery, Centre Hospitalier de l'Universite de Montreal, 
      Montreal, Quebec, Canada.
FAU - Stevens, Louis-Mathieu
AU  - Stevens LM
FAU - Mansour, Samer
AU  - Mansour S
FAU - Prieto, Ignacio
AU  - Prieto I
FAU - Salem, Reda
AU  - Salem R
FAU - Baron, Chantal
AU  - Baron C
FAU - Roy, Denis-Claude
AU  - Roy DC
FAU - Larose, Eric
AU  - Larose E
FAU - Masckauchan, Daiana
AU  - Masckauchan D
FAU - Noiseux, Nicolas
AU  - Noiseux N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121221
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
RN  - 0 (AC133 Antigen)
RN  - 0 (Antigens, CD)
RN  - 0 (Glycoproteins)
RN  - 0 (PROM1 protein, human)
RN  - 0 (Peptides)
SB  - IM
CIN - Can J Cardiol. 2013 Nov;29(11):1533.e1. PMID: 23623327
CIN - Can J Cardiol. 2013 Nov;29(11):1533.e3. PMID: 23725864
MH  - AC133 Antigen
MH  - Aged
MH  - *Antigens, CD/adverse effects
MH  - Canada
MH  - Chronic Disease
MH  - *Coronary Artery Bypass/methods
MH  - Feasibility Studies
MH  - Follow-Up Studies
MH  - *Glycoproteins/adverse effects
MH  - Humans
MH  - Injections
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation/methods
MH  - Middle Aged
MH  - Myocardial Ischemia/pathology/physiopathology/*surgery
MH  - Myocardium/*pathology
MH  - *Peptides/adverse effects
MH  - Pilot Projects
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 2012/12/26 06:00
MHDA- 2013/05/15 06:00
CRDT- 2012/12/26 06:00
PHST- 2012/04/08 00:00 [received]
PHST- 2012/08/15 00:00 [revised]
PHST- 2012/08/15 00:00 [accepted]
PHST- 2012/12/26 06:00 [entrez]
PHST- 2012/12/26 06:00 [pubmed]
PHST- 2013/05/15 06:00 [medline]
AID - S0828-282X(12)01213-5 [pii]
AID - 10.1016/j.cjca.2012.08.009 [doi]
PST - ppublish
SO  - Can J Cardiol. 2013 Apr;29(4):441-7. doi: 10.1016/j.cjca.2012.08.009. Epub 2012 
      Dec 21.